Neogap selected by EIC for BIO International Convention 2026
2026-04-28
PRESS RELEASE. Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has been selected by the European Innovation Council (EIC) to join its delegation at BIO International Convention 2026 – the world’s largest partnering event in biotechnology. As one of a limited number of selected European life science companies, Neogap will participate in the EIC Pavilion to engage with potential global partners and advance business development discussions.
San Diego, USA – host city of BIO International Convention, 22–25 June 2026.
The programme is organised by the European Innovation Council (EIC), Europe’s flagship innovation programme and largest deep-tech investor. Through its Business Acceleration Services, the EIC supports innovative companies in their commercialisation and international expansion, providing access to global partnerships, mentoring and business development opportunities.
As part of the International Trade Fairs Programme, Neogap will be part of the EIC Pavilion, as one of 15 selected companies – and the only Swedish company in the delegation – benefiting from tailored support, coaching and targeted matchmaking activities ahead of and during the conference.
Neogap is developing pTTL, a personalised cell-based immunotherapy for the treatment of solid tumours, currently being evaluated in a Phase I/II clinical trial in patients with advanced colorectal cancer.
“Being selected by the EIC to join their delegation at BIO International Convention is a strong validation of our technology and clinical progress, and reflects the growing international interest in our work. BIO is a key meeting point for the global biotech community and provides an important platform to increase our visibility, build new relationships and explore potential partnering opportunities,” says Samuel Svensson, CEO of Neogap Therapeutics.
BIO International Convention will take place in San Diego on 22–25 June 2026. For more information, please visit: https://convention.bio.org/
About Neogap’s cell-based immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy designed to enhance the patient’s own T cells to fight cancer. The therapy combines advanced DNA sequencing with T-cell expansion to deliver a personalised, precision-based treatment for solid tumours. The pTTL treatment is based on Neogap’s proprietary technologies, PIOR® and EpiTCer®, and is currently being evaluated in a Phase I/II clinical trial in patients with advanced colorectal cancer.
Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.
For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94
About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two proprietary technologies, PIOR® and EpiTCer®. PIOR® leverages patient-derived DNA sequencing data and machine learning to identify tumour-specific mutations. EpiTCer® is used to expand T cells that recognise and target the selected tumour-specific structures. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its research, please visit neogap.se and follow Neogap on LinkedIn.